|
KMID : 0367320050160020239
|
|
Journal of the Korean Academy of Child and Adolescent Psychiatry
2005 Volume.16 No. 2 p.239 ~ p.250
|
|
|
THE EFFICACY AND SAFETY OF RISPERIDONE IN CHILD & ADOLESCENT PSYCHIATRIC INPATIENT
|
|
Park Jeong-Hyun
Kim Bung-Nyun
|
|
|
Abstract
|
|
|
Objective: The purpose of this study was obtaining data on the efficacy and safety of risperidone in child and adolescent psychiatric patients.
Method: Thirty one children and adolescents (males n=18, females n=13, age ranged from 5.4 to 17.3 years) treated with risperidone were selected among child and adolescent psychiatric inpatients of Seoul National University Hospital from January, 2001 to June, 2002, and charts for them were reviewed retrospectively.
Results: The primary psychiatric disorders treated with risperidone were schizophrenia and other psychosis, bipolar I disorder with psychotic features, Tourette’’s disorder, autism spectrum disorders, mixed receptive and expressive language disorder, attention deficit-hyperactivity disorder, conduct disorder and obsessive-compulsive disorder. twelve of these had comorbid mental retardation. Primary target symptoms of risperidone were psychotic symptoms (n=13 or 41.9%), behavioral symptoms (n=10 or 32.3%) including aggression, impulsivity, hyperactivity, stereotypy nonresponsive to other psychiatric treatments, and chronic and severe tics (n=8, 25.8%). The efficacy of risperidone was measured by clinical global improvement (CGI) for target symptoms, 67.7% of subjects showed moderate or marked improvements and its therapeutic effect appeared to be maintained during at least 7.5 months. Mean daily dosage of risperidone was 0.05{pm}0.01mg/kg, the group with psychotic symptoms had significantly higher mean daily dosage (0.07mg/kg) compared with other two groups (0.04mg/kg) with behavioral symptoms or tics. A variety of adverse events were reported in this study : weight gain (n=23) most commonly reported, extrapyramidal symptoms (n=15), autonomic symptoms (n=6), sedation (n=5) and symptoms related to hyperprolactinemia (n=2) etc. Although there was no drug change related to the adverse events of risperidone, and 90% of subjects at their last visits were maintained on it, thus its tolerability appeared good.
Conclusions: Results suggest that risperidone may be relatively safe and effective drug in managing a wide variety of child and adolescent psychopathologies such as psychotic symptoms, behavioral symptoms including aggression, impulsivity, hyperactivity and stereotypy nonresponsive to other psychiatric treatments, and chronic and severe tics. Controlled and long-term studies of efficacy and safety of risperidone treatment for children and adolescents are recommended in the future.
|
|
|
KEYWORD
|
|
|
Children and adolescents, Psychopathologies, Risperidone, Efficacy, Safety
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|